肾癌靶向治疗耐药的生物学机制研究进展

Progress in the biological mechanism of targeted drug resistance in renal cell carcinoma

肾细胞癌是我国泌尿系统最常见的恶性肿瘤。肾细胞癌对放、化疗具有高度抵抗性,免疫治疗有效率极低且有明显副作用。分子靶向药物为晚期肾癌治疗揭开了崭新的一页,但靶向治疗耐药显著影响了其临床疗效。本文将就肾癌对靶向药物耐受的分子机制最新进展作一综述,以期为寻找全新的作用靶点提供新的思路。

Renal cell carcinoma is the most common malignant tumor of urinary system in China.Renal cell carcinoma is highly resistant to radiotherapy and chemotherapy,and the immunotherapy is very less effective and remains significant side effects.Molecular targeted drugs have opened a new page for the treatment of advanced renal cell carcinoma,but targeted drug resistance has significantly affected its clinical efficacy.This article will review the latest progress of molecular mechanisms of drug resistance in renal cell carcinoma,in order to provide a new idea for discovering new targets.